(Q33162197)

23 July 2017

Feasibility and safety of sequential research-related tumor core biopsies in clinical trials (English)

1 reference

23 July 2017

Anne M Noonan

3

0 references

Katherine R. Calvo

object named as

Katherine R Calvo

9

0 references

Bradford J. Wood

object named as

Bradford J Wood

7

0 references

author name string

Jung-min Lee

1

1 reference

23 July 2017

John L Hays

2

1 reference

23 July 2017

Jennifer Squires

4

1 reference

23 July 2017

Lori Minasian

5

1 reference

23 July 2017

Christina Annunziata

6

1 reference

23 July 2017

Minshu Yu

8

1 reference

23 July 2017

Nicole Houston

10

1 reference

23 July 2017

Nilofer Azad

11

1 reference

23 July 2017

Elise C Kohn

12

1 reference

23 July 2017

language of work or name

English

0 references

publication date

20 December 2012

1 reference

23 July 2017

1 reference

23 July 2017

119

1 reference

23 July 2017

1357-1364

1 reference

23 July 2017

7

1 reference

Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells

23 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3604070

Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3604070

Proteomics and biomarkers in clinical trials for drug development

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3604070

Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3604070

Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3604070

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3604070

Performing nondiagnostic research biopsies in irradiated tissue: a review of scientific, clinical, and ethical considerations

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3604070

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3604070

Trastuzumab--mechanism of action and use in clinical practice

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3604070

A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3604070

Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3604070

Clinical trial designs for predictive marker validation in cancer treatment trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3604070

Laparoscopy in the massively obese female.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3604070

Phase I clinical trial design in cancer drug development.

21 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FCNCR.27916

Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FCNCR.27916

Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3604070

Laparoscopic pelvic lymphadenectomy in obese women with gynecologic malignancies

31 October 2018

1 reference

12 December 2020

Percutaneous CT-guided multisampling core needle biopsy of thoracic lesions

1 reference

12 December 2020

A prospective analysis of imatinib-induced c-kit modulation in ovarian cancer

1 reference

12 December 2020

Reverse phase protein microarrays for theranostics and patient-tailored therapy

1 reference

12 December 2020

Hysterectomy for obese women with endometrial cancer: laparoscopy or laparotomy?

1 reference

12 December 2020

Identifiers

DOI

10.1002/CNCR.27916

1 reference

23 July 2017

1 reference

23 July 2017

1 reference